NCT05373823 MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
| NCT ID | NCT05373823 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rutgers, The State University of New Jersey |
| Condition | Melanoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 385 participants |
| Start Date | 2023-03-06 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 385 participants in total. It began in 2023-03-06 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This project, mySmartSkin (MSS), includes an innovative Type 1 hybrid effectiveness-implementation trial designed to enhance the effects of MSS and simultaneously assess key implementation outcomes (e.g., cost, adoption) as well as contextual factors important for scale-up in community and health care settings where melanoma survivors receive follow-up care. A type 1 hybrid effectiveness-implementation design allows us to engage multilevel stakeholders throughout this process, evaluate the effectiveness of the enhanced MSS, and identify critical factors for wide-scale implementation. Aim 1 will focus on enhancing the previous version of MSS by collaborating with multi-level stakeholders in qualitative interviews and usability testing. Aim 2 will evaluate the effects of enhanced MSS on thorough skin-self examinations (SSE) in a randomized-control trial (RCT) and examine its impact on the diagnosis of new/recurrent melanomas. Aim 3 will focus on assessing selected implementation outcomes and identify factors relevant to future scale-up for widespread dissemination and implementation.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of primary pathologic stage 0-III cutaneous malignant melanoma * Three months to five years post-surgery * No current evidence of cancer * Not adherent to thorough SSE (i.e., did not check entire body at least once during the past three months) * ≥ 18 years old * Internet access * Able to speak/read English * Able to provide informed consent Exclusion Criteria: * Children
Contact & Investigator
Sharon Manne, PhD
PRINCIPAL INVESTIGATOR
Rutgers Cancer Institute of New Jersey
Frequently Asked Questions
Who can join the NCT05373823 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Melanoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05373823 currently recruiting?
Yes, NCT05373823 is actively recruiting participants. Contact the research team at mannesl@cinj.rutgers.edu for enrollment information.
Where is the NCT05373823 trial being conducted?
This trial is being conducted at New Brunswick, United States.
Who is sponsoring the NCT05373823 clinical trial?
NCT05373823 is sponsored by Rutgers, The State University of New Jersey. The principal investigator is Sharon Manne, PhD at Rutgers Cancer Institute of New Jersey. The trial plans to enroll 385 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.